BioCryst Pharmaceuticals (BCRX) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a buy rating in a report issued on Tuesday morning.

Other analysts have also recently issued reports about the company. ValuEngine upgraded BioCryst Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, August 8th. Royal Bank of Canada reiterated a buy rating and issued a $9.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. HC Wainwright restated a buy rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, August 13th. They noted that the move was a valuation call. Jefferies Financial Group restated a buy rating and set a $8.50 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, August 9th. Finally, Zacks Investment Research cut BioCryst Pharmaceuticals from a strong-buy rating to a hold rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $9.89.

NASDAQ:BCRX traded up $0.26 during trading hours on Tuesday, reaching $7.45. The company had a trading volume of 4,911 shares, compared to its average volume of 457,143. BioCryst Pharmaceuticals has a one year low of $4.12 and a one year high of $8.13. The stock has a market capitalization of $783.60 million, a price-to-earnings ratio of -9.51 and a beta of 1.64. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. The firm had revenue of $12.49 million for the quarter, compared to analysts’ expectations of $3.80 million. Research analysts expect that BioCryst Pharmaceuticals will post -0.83 EPS for the current fiscal year.

In other news, CMO William P. Sheridan sold 62,500 shares of the stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $7.03, for a total transaction of $439,375.00. Following the sale, the chief marketing officer now owns 85,713 shares in the company, valued at $602,562.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the sale, the insider now owns 140,633 shares in the company, valued at approximately $1,018,182.92. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its holdings in BioCryst Pharmaceuticals by 45.0% in the second quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock valued at $63,581,000 after acquiring an additional 3,441,498 shares during the last quarter. BlackRock Inc. boosted its holdings in BioCryst Pharmaceuticals by 3.8% in the second quarter. BlackRock Inc. now owns 7,755,951 shares of the biotechnology company’s stock valued at $44,442,000 after acquiring an additional 281,532 shares during the last quarter. VHCP Management II LLC boosted its holdings in BioCryst Pharmaceuticals by 11.0% in the second quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock valued at $14,120,000 after acquiring an additional 243,270 shares during the last quarter. Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 2.2% in the second quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock valued at $6,960,000 after acquiring an additional 25,685 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 5.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 519,060 shares of the biotechnology company’s stock valued at $2,975,000 after acquiring an additional 28,084 shares during the last quarter. Institutional investors and hedge funds own 79.89% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Read More: Understanding the different types of bonds

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply